Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- the Angeles Clinic and Research Institute
Los Angeles, California, United States
- Us Davis Cancer Center
Sacramento, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- University of Connecticut Health Center Carole and Ray Neag Comprehensive Cancer Center
Farmington, Connecticut, United States
- Miami Cancer Institute at Baptist Health, Inc
Miami, Florida, United States
- Georgia Cancer Specialists Affiliated With Northside Hospital Cancer Institute
Atlanta, Georgia, United States
- the University of Chicago Medicine
Chicago, Illinois, United States
- St. Francis Cancer Center
Topeka, Kansas, United States
- Greater Baltimore Cancer Center
Baltimore, Maryland, United States
- St. Agnes Hospital Cancer Institute
Baltimore, Maryland, United States
- the Center for Cancer and Blood Disorders (rcca Md Llc- Maryland Division)
Bethesda, Maryland, United States
- University of Michigan Hospital and Health Systems
Ann Arbor, Michigan, United States
- Health Partners Institute
Saint Louis Park, Minnesota, United States
- Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey, United States
- the Christ Hospital Hematology Oncology, Lindner Research Center
Cincinnati, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
- Greenville Health System Cancer Institute
Greenville, South Carolina, United States
- West Cancer Center
Germantown, Tennessee, United States
- Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
- Virginia Cancer Specialists
Arlington, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Jul 2014
- Primary completion
- 26 Nov 2018
- Completion
- 6 Nov 2020
- Last update posted
- 14 Feb 2022
- Registered enrollment
- 444
- Registry id
- NCT02178722
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.